Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · Pharmaceutical Preparations · Palm Beach Gardens, FL

Our rating: Neutral

Call changed from Cautious to Neutral at $307.02, moderate conviction, November 2, 2026.

Breaks if: The Neutral call turns Positive if free cash flow as a share of revenue rises above 25% for two consecutive quarterly filings — compared with roughly 18% today — confirming that the royalty model converts reported income to cash as its structure implies it should. The call turns Cautious if that same FCF margin falls below 15% for any two consecutive quarters reported before the end of 2027, or if the next annual filing shows year-on-year revenue growth below 10%; either outcome would mean a multiple pricing in real compounding cash returns is instead resting on non-cash income that does not compound.

Key figures

Market value$5.7B
Revenue, last 12 months$254M
Net income, last 12 months$51M
Free cash flow, last 12 months$91M
Price to earnings111.5×
Free cash flow yield1.6%
Dividend yield0.0%
Operating margin10.1%
Return on equity5.4%
Beta to the S&P 5000.97
Volatility, annualized37.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$79M−31.8%$-1.43−$28M
June 30, 2026$64M33.7%$2.22$24M
March 31, 2026$52M14.1%$-0.67$48M
December 31, 2025$60M39.4%$2.18$46M
September 30, 2025$115M122.8%$5.68$13M
June 30, 2025$48M14.7%$0.24$16M
March 31, 2025$45M46.3%$-2.21−$26M
December 31, 2024$43M52.4%$-1.68$28M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

14 ledger entries and 78 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.